DOI QR코드

DOI QR Code

Prognostic Impact of Elevation of Vascular Endothelial Growth Factor Family Expression in Patients with Non-small Cell lung Cancer: an Updated Meta-analysis

  • Zheng, Chun-Long (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University) ;
  • Qiu, Chen (Institute of Oncology, Provincial Hospital Affiliated to Shandong University) ;
  • Shen, Mei-Xiao (Institute of Oncology, Provincial Hospital Affiliated to Shandong University) ;
  • Qu, Xiao (Institute of Oncology, Provincial Hospital Affiliated to Shandong University) ;
  • Zhang, Tie-Hong (Institute of Oncology, Provincial Hospital Affiliated to Shandong University) ;
  • Zhang, Ji-Hong (Institute of Oncology, Provincial Hospital Affiliated to Shandong University) ;
  • Du, Jia-Jun (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University)
  • Published : 2015.03.18

Abstract

Background: The vascular endothelial growth factor family has been implicated in tumorigenesis and metastasis. The prognostic value of each vascular endothelial growth factor family member, particular VEGF/VEGFR co-expression, in patients with non-small lung cancer remains controversial. Materials and Methods: Relevant literature was identified by searching PubMed, EMBASE and Web of Science. Studies evaluating expression of VEGFs and/or VEGFRs by immunohistochemistry or ELISA in lung cancer tissue were eligible for inclusion. Hazard ratios (HRs) and 95% confidence intervals (CIs) from individual study were pooled by using a fixed- or random-effect model, heterogeneity and publication bias analyses were also performed. Results: 74 studies covering 7,631 patients were included in the meta-analysis. Regarding pro-angiogenesis factors, the expression of VEGFA (HR=1.633, 95%CI: 1.490-1.791) and VEGFR1 (HR=1.924, 95%CI: 1.220-3.034) was associated separately with poor survival. Especially, VEGFA over-expression was an independent prognostic factor in adenocarcinoma (ADC) (HR=1.775, 95%CI: 1.384-2.275) and SCC (HR=2.919, 95%CI: 2.060-4.137). Co-expression of VEGFA/VEGFR2 (HR=2.011, 95%CI: 1.405-2.876) was also significantly associated with worse survival. For lymphangiogenesis factors, the expression of VEGFC (HR=1.611, 95%CI: 1.407-1.844) predicted a poor prognosis. Co-expression of VEGFC/VEGFR3 (HR=2.436, 95%CI: 1.468-4.043) emerged as a preferable prognostic marker. Conclusions: The expression of VEGFA (particularly in SCC and early stage NSCLC), VEGFC, VEGFR1 indicates separately an unfavorable prognosis in patients with NSCLC. Co-expression VEGFA/VEGFR2 is comparable with VEGFC/VEGFR3, both featuring sufficient discrimination value as preferable as prognostic biologic markers.

Keywords

Vascular endothelial growth factor;vascular endothelial growth factor receptor;prognosis;NSCLC

References

  1. Alberg AJ, Samet JM (2003). Epidemiology of lung cancer. Chest, 123, 21-49. https://doi.org/10.1378/chest.123.1_suppl.21S
  2. Alitalo K, Carmeliet P (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell, 1, 219-27. https://doi.org/10.1016/S1535-6108(02)00051-X
  3. Anagnostou VK, Tiniakos DG, Fotinou M, et al (2011). Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients. Virchows Arch, 458, 331-40. https://doi.org/10.1007/s00428-010-1015-4
  4. Arinaga M, Noguchi T, Takeno S, et al (2003). Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer, 97, 457-64. https://doi.org/10.1002/cncr.11073
  5. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  6. Bircan A, Bircan S, Kapucuoglu N, et al (2010). Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters. Pathol Oncol Res, 16, 553-61. https://doi.org/10.1007/s12253-010-9259-5
  7. Bonnesen B, Pappot H, Holmstav J, et al (2009). Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer, 66, 314-8. https://doi.org/10.1016/j.lungcan.2009.02.013
  8. Bonnesen B, Pappot H, Holmstav J, et al (2009). Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer, 66, 314-8. https://doi.org/10.1016/j.lungcan.2009.02.013
  9. Chen G, Liu XY, Wang Z, et al (2010). Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg, 37, 546-51. https://doi.org/10.1016/j.ejcts.2009.08.005
  10. Chen SC, Shih CM, Tseng GC, et al (2011). Vascular endothelial growth factor C as a predictor of early recurrence and poor prognosis of resected stage I non-small cell lung cancer. Ann Acad Med Singapore, 40, 319-24.
  11. Cohen MH, Gootenberg J, Keegan P, et al (2007). FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 12, 713-8. https://doi.org/10.1634/theoncologist.12-6-713
  12. Dai X, Wang W, Shen-Tu Y, et al (2011). Expression and prognostic value of VEGF-C and lymphangeogenesis in lung adenocarcinoma and squamous cell carcinoma. Zhongguo Fei Ai Za Zhi, 14, 774-9.
  13. Delmotte P, Martin B, Paesmans M, et al (2002). The role of vascular endothelial growth factor in the survival of patients with lung cancer: a systematic literature review and metaanalysis. Revue des Maladies Respiratoires, 19, 577-84.
  14. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  15. Doebele RC, Conkling P, Traynor AM, et al (2012). A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol, 23, 2094-102. https://doi.org/10.1093/annonc/mdr596
  16. Donnem T, Al-Saad S, Al-Shibli K, et al (2007). Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res, 13, 6649-57. https://doi.org/10.1158/1078-0432.CCR-07-0414
  17. Donnem T, Andersen S, Al-Saad S, et al (2011). Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size. Clin Lung Cancer, 12, 106-15. https://doi.org/10.1016/j.cllc.2011.03.005
  18. Dubben HH, Beck-Bornholdt HP (2005). Systematic review of publication bias in studies on publication bias. BMJ, 331, 433-4. https://doi.org/10.1136/bmj.38478.497164.F7
  19. Dwyer T, Couper D, Walter SD (2001). Sources of heterogeneity in the meta-analysis of observational studies: the example of SIDS and sleeping position. J Clin Epidemiol, 54, 440-7. https://doi.org/10.1016/S0895-4356(00)00313-9
  20. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  21. Enatsu S, Iwasaki A, Shirakusa T, et al (2006). Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung. Eur J Cordiothorac Surg, 29, 891-5. https://doi.org/10.1016/j.ejcts.2006.03.027
  22. Ferrara N (2002). VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer, 2, 795-803. https://doi.org/10.1038/nrc909
  23. Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-74. https://doi.org/10.1038/nature04483
  24. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6. https://doi.org/10.1056/NEJM197111182852108
  25. Fontanini G, Vignati S, Boldrini L, et al (1997). Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res, 3, 861-5.
  26. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al (1998). Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res, 4, 3017-24.
  27. Gimbrone MA, Leapman SB, Cotran RS, et al (1972). Tumor dormancy in vivo by prevention of neovascularization. J Exp Med, 136, 261-76. https://doi.org/10.1084/jem.136.2.261
  28. Han H, Silverman JF, Santucci TS, et al (2001). Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol, 8, 72-9. https://doi.org/10.1007/s10434-001-0072-y
  29. Hardy RJ, Thompson SG (1998). Detecting and describing heterogeneity in meta-analysis. Stat Med, 17, 841-56. https://doi.org/10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D
  30. Hayes DF, Isaacs C, Stearns V (2001). Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia, 6, 375-92. https://doi.org/10.1023/A:1014778713034
  31. He Y, Rajantie I, Pajusola K, et al (2005). Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res, 65, 4739-46. https://doi.org/10.1158/0008-5472.CAN-04-4576
  32. Hicklin DJ, Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23, 1011-27.
  33. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. https://doi.org/10.1002/sim.1186
  34. Huang C, Liu D, Masuya D, et al (2005). Clinical application of biological markers for treatments of resectable non-smallcell lung cancers. Br J Cancer, 92, 1231-9. https://doi.org/10.1038/sj.bjc.6602481
  35. Imoto H, Osaki T, Taga S, et al (1998). Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg, 115, 1007-14. https://doi.org/10.1016/S0022-5223(98)70398-8
  36. Inamura K, Ninomiya H, Ishikawa Y, et al (2010). Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med, 134, 66-72.
  37. Inoshima N, Nakanishi Y, Minami T, et al (2002). The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res, 8, 3480-6.
  38. Ito H, Oshita F, Kameda Y, et al (2002). Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol Rep, 9, 119-23.
  39. Iwasaki A, Kuwahara M, Yoshinaga Y, et al (2004). Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg, 25, 443-8. https://doi.org/10.1016/j.ejcts.2003.11.031
  40. Jiang H, Shao W, Zhao W (2014). VEGF-C in non-small cell lung cancer: Meta-analysis. Clin Chim Acta, 427, 94-9. https://doi.org/10.1016/j.cca.2013.10.002
  41. Johnson DH, Fehrenbacher L, Novotny WF, et al (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 22, 2184-91. https://doi.org/10.1200/JCO.2004.11.022
  42. Kadota K, Huang CL, Liu D, et al (2008). The clinical significance of lymphangiogenesis and angiogenesis in nonsmall cell lung cancer patients. Eur J Cancer, 44, 1057-67. https://doi.org/10.1016/j.ejca.2008.03.012
  43. Kaira K, Yamamoto N (2010). Prognostic and predictive factors in resected non-small-cell lung cancer. Expert Opin Med Diagn, 4, 373-81. https://doi.org/10.1517/17530059.2010.506214
  44. Kajita T, Ohta Y, Kimura K, et al (2001). The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer, 85, 255-60. https://doi.org/10.1054/bjoc.2001.1882
  45. Kang YH, Kim KS, Yu YK, et al (2001). The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer. J Korean Med Sci, 16, 417-23. https://doi.org/10.3346/jkms.2001.16.4.417
  46. Kim MJ, Shin HC, Shin KC, et al (2013a). Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. Ann Diagn Pathol, 17, 85-90. https://doi.org/10.1016/j.anndiagpath.2012.07.006
  47. Kim MS, Park TI, Lee YM, et al (2013b). Expression of Id-1 and VEGF in non-small cell lung cancer. Int J Clin Exp Pathol, 6, 2102-11.
  48. Kim SJ, Rabbani ZN, Dewhirst MW, et al (2005). Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer, 49, 325-35. https://doi.org/10.1016/j.lungcan.2005.03.036
  49. Ko YH, Jung CK, Lee MA, et al (2008). Clinical significance of vascular endothelial growth factors (VEGF)-C and -D in resected non-small cell lung cancer. Cancer Res Treat, 40, 133-40. https://doi.org/10.4143/crt.2008.40.3.133
  50. Kojima H, Shijubo N, Abe S (2002). Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer, 94, 1083-93. https://doi.org/10.1002/cncr.10352
  51. Kojima H, Shijubo N, Yamada G, et al (2005). Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer, 104, 1668-77. https://doi.org/10.1002/cncr.21366
  52. Konishi T, Huang CL, Adachi M, et al (2000). The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int J Oncol, 16, 501-11.
  53. Li B, Cao X, Zhang J, et al (2004). Expression and clinical significance of vascular endothelial growth factor in human non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 7, 142-5.
  54. Li Q, Dong X, Gu W, et al (2003). Clinical significance of coexpression of VEGF-C and VEGFR-3 in non-small cell lung cancer. Chin Med J (Engl), 116, 727-30.
  55. Li X, Li C, Zhang W, et al (2005). Expressions of cyclooxygenase- 2 and vascular endothelial growth factor in human lung cancer tissue. Zhongguo Fei Ai Za Zhi, 8, 112-5.
  56. Liang RY, Liao ZS, Jiang SP, et al (2003). Expression of cyclin D1 and vascular endothelial growth factor(VEGF) in nonsmall cell lung carcinoma and their association with the prognosis. Ai Zheng, 22, 86-90.
  57. Liao M, Wang H, Lin Z, et al (2001). Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer, 33, 125-32. https://doi.org/10.1016/S0169-5002(01)00195-7
  58. Lin Q, Li M, Shen ZY, et al (2010). Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Jpn J Clin Oncol, 40, 670-6. https://doi.org/10.1093/jjco/hyq041
  59. Maekawa S, Iwasaki A, Shirakusa T, et al (2007). Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res, 27, 3735-41.
  60. Masuya D, Huang C, Liu D, et al (2001). The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer, 92, 2628-38. https://doi.org/10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F
  61. Miller VA, Kris MG, Shah N, et al (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22, 1103-9. https://doi.org/10.1200/JCO.2004.08.158
  62. Minami K, Saito Y, Imamura H, et al (2002). Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer, 38, 51-7.
  63. Mineo TC, Ambrogi V, Baldi A, et al (2004). Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol, 57, 591-7. https://doi.org/10.1136/jcp.2003.013508
  64. Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94. https://doi.org/10.1016/S0025-6196(11)60735-0
  65. Nakashima T, Huang CL, Liu D, et al (2004). Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for nonsmall cell lung cancer. Med Sci Monit, 10, 157-65.
  66. Niklinska W, Burzykowski T, Chyczewski L, et al (2001). Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer, 34, 59-64.
  67. Nishi M, Abe Y, Tomii Y, et al (2005). Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int J Oncol, 26, 1517-24.
  68. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al (2000). Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-smallcell lung cancer. Br J Cancer, 82, 1427-32. https://doi.org/10.1054/bjoc.1999.1129
  69. Odaka M, Sato S, Masubuchi M, et al (2000). Comparison of VEGF and p53 protein expression in stage I non-small cell lung cancer. Japanese J Lung Cancer, 40, 11-5. https://doi.org/10.2482/haigan.40.11
  70. Ogawa E, Takenaka K, Yanagihara K, et al (2004). Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br J Cancer, 91, 498-503. https://doi.org/10.1038/sj.bjc.6601992
  71. Ohta Y, Nozawa H, Tanaka Y, et al (2000). Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg, 119, 804-13. https://doi.org/10.1016/S0022-5223(00)70017-1
  72. Ohta Y, Tanaka Y, Watanabe G, et al (2007). Predicting recurrence following curative surgery in stage I non-small cell lung cancer patients using an angiogenesis-associated factor. J Exp Clin Cancer Res, 26, 301-5.
  73. Osaki T, Oyama T, Inoue M, et al (2001). Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. prognostic implications. Jpn J Thorac Cardiovasc Surg, 49, 545-51. https://doi.org/10.1007/BF02913530
  74. Oshika Y, Nakamura M, Tokunaga T, et al (1998). Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int J Oncol, 12, 541-4.
  75. Paesmans M, Sculier JP, Libert P, et al (1995). Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. the european lung cancer working party. J Clin Oncol, 13, 1221-30.
  76. Peters JL, Sutton AJ, Jones DR, et al (2008). Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol, 61, 991-6. https://doi.org/10.1016/j.jclinepi.2007.11.010
  77. Rades D, Setter C, Dunst J, et al (2010). Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC). Strahlenther Onkol, 186, 307-14. https://doi.org/10.1007/s00066-010-2131-4
  78. Renyi-Vamos F, Tovari J, Fillinger J, et al (2005). Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res, 11, 7344-53. https://doi.org/10.1158/1078-0432.CCR-05-1077
  79. Saad RS, Liu Y, Han H, et al (2004). Prognostic significance of HER2/neu, p53, and vascular endothelial growth factor expression in early stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Mod Pathol, 17, 1235-42. https://doi.org/10.1038/modpathol.3800171
  80. Saintigny P, Kambouchner M, Ly M, et al (2007). Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer, 58, 205-13. https://doi.org/10.1016/j.lungcan.2007.06.021
  81. Schiller JH, Larson T, Ou SH, et al (2009). Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol, 27, 3836-41. https://doi.org/10.1200/JCO.2008.20.8355
  82. Seto T, Higashiyama M, Funai H, et al (2006). Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer, 53, 91-6. https://doi.org/10.1016/j.lungcan.2006.02.009
  83. Sheng H, Aoe M, Doihara H, et al (2000). Prognostic value of vascular endothelial growth factor expression in primary lung carcinoma. Acta Med Okayama, 54, 119-26.
  84. Shibusa T, Shijubo N, Abe S (1998). Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res, 4, 1483-7.
  85. Shou Y, Hirano T, Gong Y, et al (2001). Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer, 85, 1706-12. https://doi.org/10.1054/bjoc.2001.2137
  86. Spratlin JL, Cohen RB, Eadens M, et al (2010). Phase I pharmacologic and biologic study of ramucirumab (IMC- 1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol, 28, 780-7. https://doi.org/10.1200/JCO.2009.23.7537
  87. Starnes SL, Pathrose P, Wang J, et al (2012). Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer. Ann Thorac Surg, 93, 1606-12. https://doi.org/10.1016/j.athoracsur.2012.01.048
  88. Stead LF, Berri S, Wood HM, et al (2012). The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma. Neoplasia, 14, 1075-86. https://doi.org/10.1593/neo.121380
  89. Sternberg CN, Davis ID, Mardiak J, et al (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 28, 1061-8. https://doi.org/10.1200/JCO.2009.23.9764
  90. Sun JG, Wang Y, Chen ZT, et al (2009). Detection of lymphangiogenesis in non-small cell lung cancer and its prognostic value. J Exp Clin Cancer Res, 28, 21. https://doi.org/10.1186/1756-9966-28-21
  91. Takanami I, Tanaka F, Hashizume T, et al (1997). Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res, 17, 2811-4.
  92. Tanaka F, Ishikawa S, Yanagihara K, et al (2002). Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res, 62, 7124-9.
  93. Tanaka F, Yanagihara K, Otake Y, et al (2004). Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer. Cancer Sci, 95, 371-6. https://doi.org/10.1111/j.1349-7006.2004.tb03218.x
  94. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  95. Tomita M, Matsuzaki Y, Shimizu T, et al (2005). Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value. Respirol, 10, 31-5. https://doi.org/10.1111/j.1440-1843.2005.00655.x
  96. Ucvet A, Kul C, Gursoy S, et al (2011). Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma. Arch Bronconeumol, 47, 397-402.
  97. Vermeulen PB, Gasparini G, Fox SB, et al (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer, 38, 1564-79. https://doi.org/10.1016/S0959-8049(02)00094-1
  98. Volm M, Koomagi R, Mattern J (1997). Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer, 74, 64-8. https://doi.org/10.1002/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I
  99. Walter SD (1997). Variation in baseline risk as an explanation of heterogeneity in meta-analysis. Stat Med, 16, 2883-900. https://doi.org/10.1002/(SICI)1097-0258(19971230)16:24<2883::AID-SIM825>3.0.CO;2-B
  100. Wang M, Liu BG, Yang ZY, et al (2012). Significance of survivin expression: Prognostic value and survival in stage III nonsmall cell lung cancer. Exp Ther Med, 3, 983-8.
  101. Yamashita T, Uramoto H, Onitsuka T, et al (2010). Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer, 70, 320-8. https://doi.org/10.1016/j.lungcan.2010.02.013
  102. Yan W, Wistuba, II, Emmert-Buck MR, et al (2011). Squamous cell carcinoma-similarities and differences among anatomical sites. Am J Cancer Res, 1, 275-300.
  103. Yano T, Tanikawa S, Fujie T, et al (2000). Vascular endothelial growth factor expression and neovascularisation in nonsmall cell lung cancer. Eur J Cancer, 36, 601-9. https://doi.org/10.1016/S0959-8049(99)00327-5
  104. Yi J, Pan T (2004). Expression of vascular endothelial growth factor C and its receptor VEGF-R3 and their significance in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 7, 488-92.
  105. Yilmaz A, Ernam D, Unsal E, et al (2007). Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res, 38, 764-8. https://doi.org/10.1016/j.arcmed.2007.04.005
  106. Yoo J, Jung JH, Lee MA, et al (2007). Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci, 22, 318-25. https://doi.org/10.3346/jkms.2007.22.2.318
  107. Yurdakul A, Akyurek N, Yilmaz S, et al (2012). Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growthfactor expression in nonsmall cell lung cancer. Turkish J Med Sci, 42, 281-8.
  108. Zhan P, Wang J, Lv XJ, et al (2009). Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol, 4, 1094-103. https://doi.org/10.1097/JTO.0b013e3181a97e31
  109. Zhang HZ, Wei YP, Li HG, et al (2006). Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao, 26, 1307-10.
  110. Zhang L, Meng L, Wang L, et al (2004). The clinical significance of detection of vascular endothelial growth factor and CD44v6 expression in human non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 7, 427-30.
  111. Zhou S, Xu S, Zhang H, et al (2007). Prognostic significance of angiogenesis and blood vessel invasion in stage I non-small cell lung cancer after complete surgical resection. Zhongguo Fei Ai Za Zhi, 10, 29-33.

Cited by

  1. Contribution of Macrophage Migration Inhibitory Factor -173G/C Gene Polymorphism to the Risk of Cancer in Chinese Population vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4597
  2. Exosomal miRNAs as biomarkers of recurrent lung cancer vol.37, pp.8, 2016, https://doi.org/10.1007/s13277-016-4939-8
  3. Ramucirumab in the treatment of non-small cell lung cancer vol.16, pp.5, 2017, https://doi.org/10.1080/14740338.2017.1313226
  4. Fibroblast Growth Factor Receptor 1 (FGFR1), Partly Related to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Microvessel Density, is an Independent Prognostic Factor for Non-Small Cell Lung Cancer vol.23, pp.1643-3750, 2017, https://doi.org/10.12659/MSM.899005
  5. Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway vol.36, pp.1, 2017, https://doi.org/10.1186/s13046-017-0495-3
  6. Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis vol.18, pp.1, 2018, https://doi.org/10.1186/s12890-018-0702-9